Skip to content

SVF Combined With Functional Self-assembling Peptide Nanofiber Hydrogels in the Treatment of Spinal Cord Injury

Safety and Feasibility of Stromal Vascular Fraction (SVF) Combined With Functional Self-assembling Peptide Nanofiber Hydrogels in the Treatment of Spinal Cord Injury

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05967325
Enrollment
15
Registered
2023-08-01
Start date
2023-07-15
Completion date
2025-07-15
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Safety Issues

Brief summary

Traumatic spinal cord injury (SCI) is a severe medical problem experienced by people worldwide with high mortality and long term morbidity. Although progress has been made in understanding cellular and molecular mechanisms of SCI, treatment and management protocols aimed at ameliorating neurologic damage in patients remain ineffective. Cells and biomaterials offer new hope for the treatment of SCI. Up to now, there have been many studies on the treatment of SCI using cells and biomaterials. Stromal Vascular Fraction (SVF) is a heterogeneous mixture of cells obtained from adipose tissue. These cells include adipose-derived stem cells, endothelial cells, endothelial progenitor cells, pericytes, T cells, and other immune cells. SVF has strong self-renewal, proliferation and differentiation potential, it can replace necrotic cells and synthesize a variety of bioactive factors through paracrine and autocrine, activate cell and vascular regeneration pathways. Therefore, SVF shows significant advantages. The sequence of functional self-assembling peptide nanofiber hydrogels (hereinafter referred to as hydrogels) is HGF(RADA)4RIKVAV (H: histidine; G: Glycine; F: phenylalanine; R: arginine; A: Alanine; D: aspartic acid; I: isoleucine; K: Lysine; V: valerine). The hydrogel is based on the short peptide RADA16 ((RADA)4, which is already available in the product PuramatrixTM for clinical hemostasis and cell culture, but the aqueous solution of PuramatrixTM is acidic which harms cells and tissues upon direct contact. While the hydrogels in this study is pH neutral and does not harm cells and tissues. Articles published by the provider demonstrate that hydrogels can support 3D stem cell growth, have good biocompatibility in vivo (animal spinal cord), and promote neural regeneration after SCI. The chemical structure of the hydrogels is simple and clear, and the degradation product is amino acid. Therefore, SVF and the hydrogel from functional self-assembling peptide are combined for SCI repair in the study.

Interventions

PROCEDUREStromal Vascular Fraction (SVF) combined with Functional self-assembling peptide nanofiber hydrogels

Transplantation of SVF and biomimetic nanohydrogel

Sponsors

Kunming Tongren Hospital
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Male or female adults, 18-60 years of age, with a clinical diagnosis of chronic traumatic SCI (≥ 3 months after SCI) 2. Neurological examination: ASIA-A 3. Both the spinal and neurological levels of injury were between T1-T12 4. Subjects must be able to read, write and complete visual analogue scale 5. Voluntarily signs and dates an informed Consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific procedures.

Exclusion criteria

1. Subjects with osteoporosis or had joint disease 2. Severe head injury 3. Severe pressure sore 4. Sign of kidney, cardiovascular, liver disorders 5. Subjects with internal medical and/or infectious diseases (including but not limited to Hepatitis B and HIV carriers) 6. Pregnant women or women at lactation stages 7. Medically or mentally unstable according to the judgment of the investigator 8. History of multiple sclerosis or peripheral demyelination 9. Any criteria which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline Kunming Locomotor Scale (KLS) at 12 monthsDay 0, Month 12Scale from minimum (1) to maximum (10), higher scales mean a better outcome.

Secondary

MeasureTime frameDescription
Change from Baseline American Spinal Injury Association International Standards for Neurologic Classification of Spinal Cord Injury at 12 monthsDay 0, Month 12Motor scores: bilateral upper and lower extremities total: minimum (0) to maximum (100), higher scores mean a better outcome. Sensory scores: bilateral light touch total from minimum (0) and maximum (112), bilateral pin prick from minimum (0) and maximum (112), higher scores mean a better outcome.
Change from Baseline Spinal Cord Independence Measure at 12 monthsDay 0, Month 12Score from minimum (0) to maximum (100), higher scores mean a better outcome.
Change from Baseline Walking Index for Spinal Cord Injury at 12 monthsDay 0, Month 12Score from minimum (0) to maximum (20), higher scores mean a better outcome.
Change from Baseline International Index of Erectile Function at 12 monthsDay 0, Month 12Male subjects only. Score from minimum (0) to maximum (25), higher scores mean a better outcome.
Change from Baseline Numerical rating scale at 12 monthsDay 0, Month 12Scale from minimum (0) to maximum (10), higher scales mean a worse outcome.
Change from Baseline Modified Ashworth Scale (MAS) at 12 monthsDay 0, Month 12Scale from minimum (0) to maximum (4), higher scales mean a worse outcome.

Countries

China

Contacts

Primary ContactHUI ZHU
kmzhuhui@sina.com(86)13888092115

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026